Article Text

Download PDFPDF

PS6:121 Juvenile and adult-onset systemic lupus erythematosus: a comparative study in a cohort of tunisian patients
  1. T Ben Salem,
  2. I Naceur,
  3. M Tougorti,
  4. M Lamloum,
  5. I Ben Ghorbel and
  6. MH Houman
  1. Department of internal medicine, La Rabta University Hospital, Tunis, Tunisia


Background Systemic lupus erythematosus (SLE) occurs in 10% to 20% of cases before the age of 18. The aim of this study was to describe clinical, biological and immunological features of juvenile-onset SLE and to compare them to adult-onset SLE.

Patients and methods It is a retrospective study including 246 patients with SLE (ACR criteria). Patients were divided in two groups: juvenile-onset SLE (onset age <18 years) and adult-onset (age was between 18 and 50 years). Data were analysed and compared. P value was considered significant if <0.05.

Results Juvenile-onset SLE (jSLE) was diagnosed in 23 women and two men. Adult-onset disease (aSLE) was seen in 167 women and 12 men (no difference in sex-ratio).

Mean age at disease onset was 14.35±2.85 years in jSLE group and mean age at diagnosis was 16.25±4.38 years. Mean delay from SLE onset to diagnosis was 18 months in jSLE (similar to aSLE).

At disease onset, malar rash (88% vs 65.7%; p=0.025) and Raynaud’s phenomena (57.1% vs 34.3%; p=0.044) were significantly more frequent in young patients whereas lupus nephritis (36% vs 36.4%) and neurological involvements (12.5% vs 12.9%) were as frequent as in jSLE than in aSLE.

During follow up of patients with jSLE, frequencies of clinical manifestations were as follow: cutaneous manifestations (92%), lupus nephritis (56%), pericarditis (39%) and neurological involvements (25%) and had no statistical differences from aSLE.

Anaemia was noted in 82.6%, leucopenia in 52.2% of jSLE patients without statistical differences whereas thrombocytopenia was significantly more frequent (39.1% vs 20.6%; p=0.046).

Antinuclear antibodies, anti-DNA and anti-ENA were positive in 100%, 81% and 86.7% of jSLE respectively (no differences with aSLE). Anti-Sm antibodies were significantly more frequent in jSLE (92.3% vs 62%; p=0.033). Infections were diagnosed in 25% of jSLE (vs 25.9%).

Corticosteroids and immunosuppressive therapy prescription was comparable in both groups. Mortality rate was higher in jSLE (23.8% vs 9.4%.p=0.065).

Conclusion Mortality rate was higher in young SLE patients although severe manifestations and infections weren’t more frequent in this group

  • Juvenile-Onset
  • Adult-Onset
  • Systemic Manifestations

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.